MicroRNA-148b Inhibits the Malignant Biological Behavior of Melanoma by Reducing Sirtuin 7 Expression Levels

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Dec 4

PMID 33274232

Citations 1

Authors

Rui Sun

Meiliang Guo

Xiaojing Fan

Qinqin Meng

Dingfen Yuan

Xinrong Yang

Kexiang Yan

Hui Deng

Affiliations

Soon will be listed here.

Abstract

There is growing evidence that microRNA-148b (miR-148b) can inhibit the growth of malignant cells while sirtuin 7 (SIRT7) may perform its carcinogenic effect by deacetylating H3K18. This study investigated the mechanism of miR-148b/SIRT7 on how it affects the malignant biological behavior of melanoma. It was established that the expression of miR-148b was downregulated in melanoma while that of SIRT7 was upregulated but negatively regulated by miR-148b through binding to the 3'UTR of SIRT7. Ectopic expression of miR-148b reduced the proliferation, migration, and invasion of melanoma cells, but SIRT7 reversed these functions of miR-148b. Moreover, tumor growth and metastasis experiments showed that miR-148b could significantly suppress proliferation and metastasis of melanoma . Overall, miR-148b inhibits the malignant biological behavior of melanoma by reducing the expression level of SIRT7. The development of miR-148b as a novel potential therapeutic approach for melanoma may be possible in the future.

Citing Articles

Targeting sirtuins for cancer therapy: epigenetics modifications and beyond.

Shen H, Qi X, Hu Y, Wang Y, Zhang J, Liu Z Theranostics. 2024; 14(17):6726-6767.

PMID: 39479446 PMC: 11519805. DOI: 10.7150/thno.100667.

References

Wang H, Lu R, Xie S, Zheng H, Wen X, Gao X . SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells. Asian Pac J Cancer Prev. 2015; 16(8):3573-7. DOI: 10.7314/apjcp.2015.16.8.3573. View

Mou Z, Xu X, Dong M, Xu J . MicroRNA-148b Acts as a Tumor Suppressor in Cervical Cancer by Inducing G1/S-Phase Cell Cycle Arrest and Apoptosis in a Caspase-3-Dependent Manner. Med Sci Monit. 2016; 22:2809-15. PMC: 4982527. DOI: 10.12659/msm.896862. View

Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

Nagarajan P, Curry J, Ning J, Piao J, Torres-Cabala C, Aung P . Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2016; 23(8):2093-2104. DOI: 10.1158/1078-0432.CCR-16-2126. View

Dror S, Sander L, Schwartz H, Sheinboim D, Barzilai A, Dishon Y . Melanoma miRNA trafficking controls tumour primary niche formation. Nat Cell Biol. 2016; 18(9):1006-17. DOI: 10.1038/ncb3399. View

Houtkooper R, Pirinen E, Auwerx J . Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012; 13(4):225-238. PMC: 4872805. DOI: 10.1038/nrm3293. View

Diaz-Martinez M, Benito-Jardon L, Alonso L, Koetz-Ploch L, Hernando E, Teixido J . miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res. 2017; 78(4):1017-1030. PMC: 5815895. DOI: 10.1158/0008-5472.CAN-17-1318. View

Wang X, Song Y . MicroRNA-340 inhibits the growth and invasion of angiosarcoma cells by targeting SIRT7. Biomed Pharmacother. 2018; 103:1061-1068. DOI: 10.1016/j.biopha.2018.04.148. View

Kai K, Dittmar R, Sen S . Secretory microRNAs as biomarkers of cancer. Semin Cell Dev Biol. 2017; 78:22-36. DOI: 10.1016/j.semcdb.2017.12.011. View

10.

Kurylowicz A, Owczarz M, Polosak J, Jonas M, Lisik W, Jonas M . SIRT1 and SIRT7 expression in adipose tissues of obese and normal-weight individuals is regulated by microRNAs but not by methylation status. Int J Obes (Lond). 2016; 40(11):1635-1642. DOI: 10.1038/ijo.2016.131. View

11.

Winter J, Jung S, Keller S, Gregory R, Diederichs S . Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009; 11(3):228-34. DOI: 10.1038/ncb0309-228. View

12.

Lee H, Jung W, Lee E, Chang H, Choi J, Kim H . SIRT7, H3K18ac, and ELK4 Immunohistochemical Expression in Hepatocellular Carcinoma. J Pathol Transl Med. 2016; 50(5):337-44. PMC: 5042897. DOI: 10.4132/jptm.2016.05.20. View

13.

Roth M, Chen W . Sorting out functions of sirtuins in cancer. Oncogene. 2013; 33(13):1609-20. PMC: 4295628. DOI: 10.1038/onc.2013.120. View

14.

Li L, Bhatia R . The controversial role of Sirtuins in tumorigenesis - SIRT7 joins the debate. Cell Res. 2012; 23(1):10-2. PMC: 3541655. DOI: 10.1038/cr.2012.112. View

15.

Jiang Z, Zhang J, Chen F, Sun Y . MiR-148b suppressed non-small cell lung cancer progression via inhibiting ALCAM through the NF-κB signaling pathway. Thorac Cancer. 2019; 11(2):415-425. PMC: 6997015. DOI: 10.1111/1759-7714.13285. View

16.

Ziari K, Zarea M, Gity M, Fayyaz A, Yahaghi E, Darian E . Retraction Note to: Downregulation of miR-148b as biomarker for early detection of hepatocellular carcinoma and may serve as a prognostic marker. Tumour Biol. 2016; 37:16401. DOI: 10.1007/s13277-016-5477-0. View

17.

Shobatake C, Miyagawa F, Ogawa K, Azukizawa H, Hirai T, Kuwahara M . Preoperative assessment of tumour thickness and vascularity using high-frequency ultrasonography in ten cases of cutaneous melanoma. Eur J Dermatol. 2018; 28(2):256-258. DOI: 10.1684/ejd.2018.3223. View

18.

Ieong C, Ma J, Lai W . RALBP1 regulates oral cancer cells via Akt and is a novel target of miR-148a-3p and miR-148b-3p. J Oral Pathol Med. 2019; 48(10):919-928. DOI: 10.1111/jop.12936. View

19.

Barber M, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z . SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012; 487(7405):114-8. PMC: 3412143. DOI: 10.1038/nature11043. View

20.

Friedrich M, Pracht K, Mashreghi M, Jack H, Radbruch A, Seliger B . The role of the miR-148/-152 family in physiology and disease. Eur J Immunol. 2017; 47(12):2026-2038. DOI: 10.1002/eji.201747132. View